Back to Search
Start Over
The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19.
- Source :
-
Value in Health . May2022, Vol. 25 Issue 5, p744-750. 7p. - Publication Year :
- 2022
-
Abstract
- <bold>Objectives: </bold>This study aimed to estimate the cost-effectiveness of remdesivir, the first novel therapeutic to receive Emergency Use Authorization for the treatment of hospitalized patients with COVID-19, and identify key drivers of value to guide future pricing and reimbursement efforts.<bold>Methods: </bold>A Markov model evaluated the cost-effectiveness of remdesivir in patients hospitalized with COVID-19 from a US healthcare sector perspective. A lifetime time horizon captured potential long-term costs and outcomes. Model outcomes included discounted total costs, life-years, and quality-adjusted life-years (QALYs). Remdesivir was modeled as an addition to standard of care and compared with standard of care alone, including dexamethasone for patients requiring respiratory support. COVID-19 hospitalizations were assumed to be reimbursed through a single payment based on the respiratory support received alongside a remdesivir carveout payment in the base case. Sensitivity and scenario analyses identified key drivers.<bold>Results: </bold>At a unit price of $520 per vial and assuming no survival benefit with remdesivir, the incremental cost-effectiveness was $298 200/QALY for patients with moderate to severe COVID-19 and $1 847 000/QALY for patients with mild COVID-19. Although current data do not support a survival benefit, if one was assumed, the cost-effectiveness estimate was $50 100/QALY for the moderate to severe population and $103 400/QALY for the mild population. Another key driver included the hospitalization payment structure (per diem vs bundled payment).<bold>Conclusions: </bold>With the current evidence available, remdesivir's price is too high to align with its expected health gains for hospitalized patients with COVID-19. Results from this study provide a rationale for iterative health technology assessment. [ABSTRACT FROM AUTHOR]
- Subjects :
- *COVID-19
*REMDESIVIR
*HOSPITAL patients
*COST effectiveness
*COVID-19 treatment
Subjects
Details
- Language :
- English
- ISSN :
- 10983015
- Volume :
- 25
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Value in Health
- Publication Type :
- Academic Journal
- Accession number :
- 156519668
- Full Text :
- https://doi.org/10.1016/j.jval.2021.11.1378